[1] Bauer V, Sotnikova R. Nitric oxide:the endothelium-derived relaxing factor and its role in endothelial functions[J]. General Physiology and Biophysics, 2010, 29(4):319-340.
[2] Kietadisorn R, Juni R P, Moens A L. Tackling endothelial dysfunction by modulating NOS uncoupling:new insights into its pathogenesis and therapeutic possibilities[J]. American Journal of Physiology,Endocrinology and Metabolism, 2012, 302(5):E481-E495.
[3] Pall M L. The NO/ONOO-cycle as the central cause of heart failure[J]. International Journal of Molecular Sciences,2013, 14(11):22274-22330.
[4] Zhao B, Shen J, Hu J, et al. Synergic effects of NO and oxygen free radicals in the injury of ischemia-reperfused myocardium:ESR studies on NO free radicals generated from ischemia-reperfused myocardium[J]. Science in China,Series C, Life sciences/Chinese Academy of Sciences,1996, 39(5):491-500.
[5] Shen J, Wang J, Zhao B, et al. Effects of EGb 761 on nitric oxide and oxygen free radicals, myocardial damage and arrhythmia in ischemia-reperfusion injury in vivo[J]. Biochimica et Biophysica Acta, 1998, 1406(3):228-236.
[6] Shen J G, Quo X S, Jiang B, et al. Chinonin, a novel drug against cardiomyocyte apoptosis induced by hypoxia and reoxygenation[J]. Biochimica et Biophysica Acta,2000, 1500(2):217-226.
[7] Zhao B, Shen J, Li M, et al. Scavenging effect of Chinonin on NO and oxygen free radicals and its protective effect on the myocardium from the injury of ischemia-reperfusion[J]. Biochimica et Biophysica Acta,1996, 1315(2):131-137.
[8] Shen J, Qiu X, Jiang B, et al. Nitric oxide and oxygen radicals induced apoptosis via bcl-2 and p53 pathway in hypoxia-reoxygenated cardiomyocytes[J]. Science in China,Series C, Life sciences/Chinese Academy of Sciences, 2003, 46(1):28-39.
[9] Zhao B. "Double Edge" effects of nitric oxide free radical in cardio-brain-vascular diseases and health studied by ESR[J]. Chinese Journal of Magnetic Resonance, 2015, 32(2):195-207.
[10] Hayward C, Patel H, Lyon A. Gene therapy in heart failure:SERCA2a as a therapeutic target[J]. Circulation Journal:Official Journal of the Japanese Circulation Society,2014, 78(11):2577-2587.
[11] Sag C M, Wagner S, Maier L S. Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes[J]. Free Radical Biology & Medicine, 2013, 63:338-349.
[12] Janssens S, Pokreisz P, Schoonjans L, et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction[J]. Circulation Research,2004, 94(9):1256-1262.
[13] Hlavackova L, Vrankova S, Janega P, et al. The effect of indapamide on development of myocardial hypertrophy and fibrosis in L-NAME-induced hypertension in rat[J]. Physiological Research,2011, 60(6):845-852.
[14] Tang L, Wang H, Ziolo M T. Targeting NOS as a therapeutic approach for heart failure[J]. Pharmacology & Therapeutics,2014, 142(3):306-315.
[15] Marti C N, Gheorghiade M, Kalogeropoulos A P, et al. Endothelial dysfunction, arterial stiffness, and heart failure[J]. Journal of the American College of Cardiology,2012, 60(16):1455-1469.
[16] Afanas'ev I. ROS and RNS signaling in heart disorders:could antioxidant treatment be successful?[J]. Oxidative Medicine and Cellular Longevity,2011, 2011:293769.
[17] Takimoto E, Champion H C, Li M, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load[J]. The Journal of Clinical Investigation,2005, 115(5):1221-1231.
[18] Liu X, Fassett J, Wei Y, et al. Regulation of DDAH1 as a potential therapeutic target for treating cardiovascular diseases[J]. Evidence-based Complementary and Alternative Medicine,2013, 2013:619207.
[19] Sayed N, Kim D D, Fioramonti X, et al. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance[J]. Circulation Research,2008, 103(6):606-614.
[20] Rector T S, Bank A J, Mullen K A, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure[J]. Circulation,1996, 93(12):2135-2141.
[21] Kralova E, Doka G, Pivackova L, et al. l-Arginine attenuates cardiac dysfunction, but further down-regulates alpha-Myosin heavy chain expression in isoproterenol-induced cardiomyopathy[J]. Basic & Clinical Pharmacology & Toxicology,2015, 117(4):251-260.
[22] Walker A F, Marakis G, Morris A P, et al. Promising hypotensive effect of hawthorn extract:a randomized double-blind pilot study of mild, essential hypertension[J]. Phytotherapy Research:PTR, 2002, 16(1):48-54.
[23] Zick S M, Vautaw B M, Gillespie B, et al. Hawthorn extract randomized blinded chronic heart failure (HERB CHF) trial[J]. European Journal of Heart Failure,2009, 11(10):990-999.
[24] Li L D, Li Y G, Gao F H, et al. Studies on hawthorn and its active principle. Ⅱ. Effects on cultured rat heart cells deprived of oxygen and glucose[J]. Journal of Traditional Chinese Medicine,1984, 4(4):289-292.
[25] Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea F M. Astaxanthin:a review of its chemistry and applications[J]. Critical Reviews in Food Science and Nutrition,2006, 46(2):185-196.
[26] Monroy-Ruiz J, Sevilla M A, Carron R, et al. Astaxanthin-enriched-diet reduces blood pressure and improves cardiovascular parameters in spontaneously hypertensive rats[J]. Pharmacological Research,2011, 63(1):44-50.
[27] van der Veen R C. Nitric oxide and T helper cell immunity[J]. International Immunopharmacology, 2001, 1(8):1491-1500.
[28] Bidri M, Feger F, Varadaradjalou S, et al. Mast cells as a source and target for nitric oxide[J]. International Immunopharmacology,2001, 1(8):1543-1558.
[29] Miranda M S, Sato S, Mancini-Filho J. Antioxidant activity of the microalga Chlorella vulgaris cultered on special conditions[J]. Bollettino Chimico Farmaceutico,2001, 140(3):165-168.